|
Hep C Study Reveals Taribavirin a Good Alternative to Ribavirin
At the end of a 48-week, Phase IIb study, taribavirin shows similar effectiveness as ribavirin in reducing Hepatitis C viral load. However, participants taking taribavirin had a significantly lower rate of anemia....
Schering-Plough Developing Potent Protease Inhibitor for Hepatitis C
An ongoing Phase IIa study on Schering-Plough's next generation Hepatitis C protease inhibitor is encouraging. According to the company, SCH 900518 is 10 times more potent than other medications in this class and is active against highly resistant Hepatitis C...
New Drug Finds Viral Hiding Spots
A new, experimental drug helps the immune system locate a virus by flagging cells that have turned inside out. Hepatitis C is among the viruses that could benefit from Bavituximab's unique strategy of exposing a virus in hiding....
|
|
|
High Incidence of Allograft Cirrhosis in Hepatitis C Virus
Genotype 1b Infection Following Transplantation: Relationship With
Rejection Episodes
| table 3.
Factors Associated With the Development of Graft Cirrhosis in
HCV-Positive Patients Following Liver Transplantation |
|
|
Patients With
Cirrhosis
(n = 12) |
Patients
Without
Cirrhosis
(n = 69) |
P |
|
| Age |
53.2 ± 10.8 |
54.7 ± 7.4 |
.53 |
| Female sex, n (%) |
6 (50) |
19 (27.5) |
.12 |
| Pre-OLT HCC, n (%) |
2 (17) |
17 (25) |
.55 |
| Duration of histologic follow-up (mo) |
30 ± 14 |
31.8 ± 17.2 |
.32 |
| Patients with rejection episodes, n (%) |
10 (83) |
33 (48) |
.02 |
| Patients treated for rejection, n (%) |
9 (75) |
29 (42) |
.03 |
| Patients receiving OKT3 for SRR, n (%) |
2 (17) |
3 (4) |
.32 |
| Patients with early rejection, n (%)* |
9 (75) |
28 (41) |
.03 |
| Patients treated for early rejection, n (%) |
8 (67) |
25 (36) |
.05 |
| Patients with late rejection, n (%)* |
5 (42) |
8 (12) |
.009 |
| Patients treated for late rejection, n (%) |
4 (33) |
8 (12) |
.05 |
| Patients with mild rejection, n (%) |
5 (42) |
19 (27) |
.32 |
| Patients with moderate rejection, n (%) |
4 (33) |
15 (22) |
.38 |
| Patients with severe rejection, n (%) |
3 (25) |
1 (1) |
.009 |
| Number of rejection episodes |
1.2 ± 0.7 |
0.5 ± 0.6 |
.001 |
| Number of MP boluses |
3 ± 2.2 |
1.5 ± 2.1 |
.03 |
|
Abbreviations: SRR,
steroid-resistant rejection; MP, methylprednisolone.
* Early rejection was defined as
rejection occurring within the first 4 weeks following
transplantation, while late rejection refers to rejection episodes
occurring after the first month. |
Return To
Article
table Of Contents
|
|
|
